This innovative platform integrates three powerful technologies working in harmony. First, the team created gold nanoarrays—precisely engineered nanoscale structures—functionalized with special aptamers (molecular recognition elements) that act like "cancer-seeking magnets," selectively capturing tumor-derived extracellular vesicles from complex blood samples. Think of these as molecular fishing nets that only catch cancer-related vesicles while letting everything else pass through.
Second, the platform harnesses CRISPR/Cas13a technology—yes, the same CRISPR system that won the Nobel Prize—but repurposed for ultra-sensitive detection rather than gene editing. The CRISPR-based sensor is highly accurate in identifying cancer-related miRNAs (miRNA-21 and miRNA-23a) linked to colorectal cancer. When the CRISPR system encounters its target miRNA, it triggers a cascade that amplifies the detection signal, enabling the identification of even minute amounts of these cancer biomarkers.
Third, and perhaps most ingeniously, the team developed specialized liposomes (synthetic lipid bubbles) that carry the CRISPR detection probes. These liposomes fuse with the captured extracellular vesicles, forming "nanoscale reactors"—femtoliter-sized chambers where the detection reaction takes place. This fusion process is crucial: it preserves the integrity of miRNAs within the vesicles (preventing degradation) while concentrating the detection components into a small volume, dramatically boosting sensitivity.
The results are impressive. The platform achieves a detection limit of just 25 extracellular vesicles (EVs) per microliter—extraordinarily sensitive compared to conventional methods. It works across a wide range of EV concentrations (10 to 1 million particles per microliter), making it suitable for clinical applications. Importantly, this technology completely bypasses the labor-intensive, destructive processes of traditional methods: there's no need to break open vesicles, extract RNA, amplify it, or perform complex laboratory procedures. The entire detection happens on a single chip within intact vesicles.
To rigorously validate their platform, the research team tested it using three increasingly complex models. They started with standard 2D-cell cultures to establish a baseline, then moved to sophisticated 3D-vascularized tumor spheroids that mimic the tumor microenvironment, including blood vessels and supporting cells. Finally, they validated the technology using actual plasma samples from colorectal cancer patients and healthy controls. The platform successfully distinguished between cancer patients and healthy individuals, with miRNA measurements comparable to the gold-standard RT-qPCR technique—but much faster and simpler.
By combining two biomarkers (miRNA-21 and miRNA-23a), the platform improves diagnostic accuracy and reduces false positives and negatives. Utilizing multiple biomarkers is particularly important because individual biomarkers can vary between patients, but a panel of markers provides a more reliable diagnosis.
Beyond colorectal cancer, the platform's modular design makes it adaptable across a broad range of applications. These aptamers can be switched out to focus on various cancers or other clinical conditions, such as Alzheimer's disease (AD). The CRISPR probes can be customized to detect any RNA biomarker of interest. And the gold nanoarray provides a scalable, reproducible foundation for clinical translation.
In short, this research represents a significant leap forward in precision oncology. By enabling ultra-sensitive, selective, and rapid cancer biomarker detection from a simple blood draw, this technology promises to transform how we diagnose cancer, monitor treatment response, and make therapeutic decisions. The platform streamlines complex diagnostic workflows into a single, user-friendly chip that could one day be routinely used in clinical settings—bringing us closer to truly personalized cancer care and improving patient outcomes through earlier detection and better monitoring.
Future developments will focus on expanding to multiplex detection (analyzing many biomarkers simultaneously) and achieving single-vesicle resolution to understand the heterogeneity and specific molecular signatures of different EV subpopulations. These advances will deepen our understanding of cancer biology while providing clinicians with even more precise diagnostic and prognostic tools.
Publication: M. Chen, H. K. Choi, L. L. Goldston, Y. Hou, C. Jiang, K.-B. Lee, Advanced Cancer Liquid Biopsy Platform for miRNA Detection in Extracellular Vesicles Using CRISPR/Cas13a and Gold Nanoarrays. ACS Nano 2025. https://doi.org/10.1021/acsnano.5c06940